Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21113934 | 0.87 | L3MBTL1 (0.41) | LSSMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21113953 | 0.85 | LSS (0.41) | LSSMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21163674 | 0.85 | LSS (0.41) | LSSMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21114066 | 0.84 | LSS (0.39) | LSSMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21122103 | 0.83 | LSS (0.39) | LSSMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21114072 | 0.81 | LSS (0.63) | LSSMEN1KMT2A | |
| SCHEMBL21114091 | 0.74 | L3MBTL1 (0.40) | LSSMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21114060 | 0.73 | NSD2 (0.43) | LSSMEN1KMT2ANPC1RAB9A | |
| SCHEMBL21114046 | 0.73 | NSD2 (0.43) | LSSMEN1KMT2ANPC1RAB9A | |
| SCHEMBL6396448 | 0.73 | MAOB (0.41) | NPC1RAB9ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
| WO-2019136314-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | LSS 438/4885MEN1 3651/4885KMT2A 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.